Merz receives CE mark for Radiesse (+) Lidocaine

Merz Pharma has announced that its dermal filler Radiesse (+) Lidocaine, with integral 0.3% lidocaine, has received the CE mark and will soon be available to physicians in Europe.

Radiesse Lidocaine provides an immediate lifting effect and stimulates the natural production of collagen, providing lasting results, as well as significant reduction in pain due to the addition of lidocaine within each syringe.

“For many years, Radiesse has been a cornerstone of Merz’s global aesthetics portfolio. We are excited to introduce Radiesse Lidocaine, a technology that delivers the trusted properties of Radiesse along with enhanced patient comfort,” stated Can Gumus, vice president of global marketing aesthetics for Merz Pharmaceuticals. “Merz’s research and development programs are strongly committed to meeting key unmet needs of physicians and patients around the world. The addition of Radiesse Lidocaine is an important step as we continue to build on the unique technology platform underlying Radiesse.”

Radiesse Lidocaine injectable implant is an opaque, dermal filler that contains a small quantity of local anaesthetic. In Europe, Radiesse Lidocaine is indicated for plastic reconstructive procedures, including deep dermal and subdermal soft tissue augmentation of the facial area and for restoration and correction of facial volume loss. The presence of lidocaine is intended to reduce patient pain and to enhance comfort during treatment.